<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01539083</url>
  </required_header>
  <id_info>
    <org_study_id>CR018751</org_study_id>
    <secondary_id>26866138-MMY-2073</secondary_id>
    <nct_id>NCT01539083</nct_id>
  </id_info>
  <brief_title>Velcade (Bortezomib) Consolidation After Transplant</brief_title>
  <acronym>VCAT</acronym>
  <official_title>An Open-label, Randomised Trial of Bortezomib Consolidation (With Thalidomide and Prednisolone) Vs Thalidomide and Prednisolone Alone in Previously Untreated Subjects With Multiple Myeloma After Receiving Bortezomib, Cyclophosphamide, Dexamethasone (VCD) Induction and Autologous Stem Cell Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Scientific Affairs, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Scientific Affairs, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if bortezomib when added to consolidation treatment
      with thalidomide and prednisolone leads to an improved response in patients with multiple
      myeloma who have undergone autologous stem cell transplant and initial treatment with
      bortezomib, cyclophosphamide, and dexamethasone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label (patients will know the identity of study treatments), randomized
      (patients will be assigned by chance to different treatments) study of bortezomib
      administered as consolidation therapy (therapy given once a remission is achieved) with
      thalidomide and prednisolone versus thalidomide and prednisolone alone in previously
      untreated patients with multiple myeloma. Multiple myeloma is a cancer of your plasma cells,
      a type of white blood cell present in your bone marrow. Patients in this study will receive
      initial therapy with bortezomib, cyclophosphamide, and dexamethasone (referred to as VCD
      induction therapy) and will undergo autologous stem cell transplant (ASCT) (a procedure where
      patients receive an infusion of immature blood cells [stem cells] from their own body to
      replenish the body's supply of healthy blood-forming cells) before randomization to one of
      two treatments: Treatment A (thalidomide for up to 12 months or until disease progression and
      prednisolone on alternate days continued indefinitely or until disease progression) or
      Treatment B (bortezomib for 32 weeks in addition to thalidomide up to 12 months or until
      disease progression and prednisolone on alternate days, continued indefinitely or until
      disease progression.

      Throughout the study, the patient's response to therapy will be assessed according to
      protocol-defined efficacy evaluations and by implementing defined disease response criteria
      (International Myeloma Working Group [IMWG] criteria). Safety will be evaluated throughout
      the study. Follow up for progression-free survival (PFS) and overall survival (OS) will be
      conducted from time of randomization to 3 years post-randomization.

      Two interim analyses are planned. The final analysis will be conducted after all patients
      have completed 12-month consolidation treatment phase or discontinued. The primary endpoint
      of number and percent of patients with complete response and very good partial response
      defined by IMWG criteria for multiple myeloma will be examined in the interim and final
      analyses after approximately 12 months of consolidation therapy. At the completion of the
      study, updated analyses of PFS and OS will be performed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 13, 2012</start_date>
  <completion_date type="Actual">January 9, 2018</completion_date>
  <primary_completion_date type="Actual">December 30, 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Consolidation Phase: Percentage of Participants With Complete Response (CR) and Very Good Partial Response (VGPR) at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>CR as per IMWG criteria is defined as negative immunofixation on the serum and urine and disappearance of soft tissue plasmacytomas and less than (&lt;) 5 percent plasma cells in bone marrow. VGPR as per IMWG criteria is defined as serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90 percent or greater reduction in serum M-protein plus urine M-protein level &lt;100 milligram (mg) per 24 hours.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Consolidation Phase: Percentage of Participants With Complete Response (CR) at Months 3, 6, 9 and 12</measure>
    <time_frame>Months 3, 6, 9 and 12</time_frame>
    <description>CR as per IMWG criteria is negative immunofixation on serum and urine and disappearance of soft tissue plasmacytomas and &lt;5 percent plasma cells in bone marrow.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Consolidation Phase: Percentage of Participants With Stringent Complete Response (sCR) at Months 3, 6, 9 and 12</measure>
    <time_frame>Months 3, 6, 9 and 12</time_frame>
    <description>sCR as per IMWG criteria is CR plus normal free light chain (FLC) ratio and absence of clonal cells in bone marrow. CR is negative immunofixation on serum and urine and disappearance of soft tissue plasmacytomas and &lt;5 percent plasma cells in bone marrow.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Consolidation Phase: Progression Free Survival (PFS)</measure>
    <time_frame>Baseline until progressive disease (up to 3 years)</time_frame>
    <description>PFS, calculated as the time between randomization to disease progression or death (regardless of cause), whichever occurred first. Progressive disease as per IMWG criteria: increase of &gt;= 25 percent from lowest response level in Serum M-component and/or (the absolute increase must be &gt;=0.5 gram per deciliter [g/dL]) Urine M-component and/or (the absolute increase must be &gt;=200 mg/24 hour. Only in participants without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain levels. The absolute increase must be &gt;10 mg/dL. Bone marrow plasma cell percentage: the absolute percent must be &gt;=10 percent. Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas. Development of hypercalcemia (corrected serum calcium &gt;11.5 mg/dL or 2.65 millimole per liter (mmol/L) that can be attributed solely to the plasma cell proliferative disorder.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Consolidation Phase: Disease-free Survival (DFS)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>DFS, defined as the duration from the start of CR to the time of relapse from CR. DFS applied only to participants in CR. CR as per IMWG criteria is negative immunofixation on serum and urine and disappearance of soft tissue plasmacytomas and &lt;5 percent plasma cells in bone marrow. Relapse from CR: reappearance of serum or urine M-protein by immunofixation or electrophoresis; development of &gt;= 5 percent plasma cells in the bone marrow; appearance of any other sign of progression (ie, new plasmacytoma, lytic bone lesion, or hypercalcaemia).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Consolidation Phase: Overall Survival (OS)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>OS was defined as the time between randomization and death. Death of a participant regardless of the cause was considered as an event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Consolidation Phase: Change From Baseline in AQOL-6D Scores at the End of the Consolidation Phase</measure>
    <time_frame>Baseline, Month 12</time_frame>
    <description>The assessment of quality of life-6D (AQoL-6D) is a multi-attribute health-related quality of life instrument (QoL). It comprises dimension scores for independent living, relationships, mental health, coping, pain, senses, and utility score for AQol-6D. Each scale ranges between 1 (best QoL) and -0.04 (worst possible QoL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Consolidation Phase: Change From Baseline in FACT/GOG-NTX Total Score at the End of the Consolidation Phase</measure>
    <time_frame>Baseline, Month 12</time_frame>
    <description>Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-NTX) consists of 10 items and evaluates symptoms and concerns associated specifically with chemotherapy-induced neuropathy. 1 FACT/GOG-NTX total score has a range of 0 to 108 with a higher score indicating better quality of life.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">256</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Bortezomib + Cyclophosphamide + Dexamethasone [VCD Induction]</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bortezomib (Velcade) 1.3 milligram per square meter (mg/m^2) subcutaneously (SC) on Days 1, 4, 8, and 11; cyclophosphamide 300 mg/m^2 orally on Days 1, 8, and 15; and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11, and 12 in three 21-day treatment cycles. Participants who completed induction phase entered into the consolidation treatment phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Thalidomide + Prednisolone [TP Consolidation]</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Thalidomide 100 mg orally, once daily until disease progression (up to maximum of 12 months) and prednisolone 50 mg orally, on every alternate day until disease progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bortezomib + Thalidomide + Prednisolone [VTP Consolidation]</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bortezomib 1.3 mg/m^2 SC every 2 weeks for 32 weeks in addition to thalidomide 100 mg orally, once daily for a maximum of 12 months or until disease progression and prednisolone 50 mg orally, on every alternate day until disease progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide</intervention_name>
    <description>Thalidomide 100 mg tablet, orally.</description>
    <arm_group_label>Thalidomide + Prednisolone [TP Consolidation]</arm_group_label>
    <arm_group_label>Bortezomib + Thalidomide + Prednisolone [VTP Consolidation]</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>Bortezomib 1.3 milligram per square meter (mg/m^2) solution for injection subcutaneously (SC).</description>
    <arm_group_label>Bortezomib + Cyclophosphamide + Dexamethasone [VCD Induction]</arm_group_label>
    <arm_group_label>Bortezomib + Thalidomide + Prednisolone [VTP Consolidation]</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide 300 mg/m^2 orally.</description>
    <arm_group_label>Bortezomib + Cyclophosphamide + Dexamethasone [VCD Induction]</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone 20 mg orally.</description>
    <arm_group_label>Bortezomib + Cyclophosphamide + Dexamethasone [VCD Induction]</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>Prednisolone 50 mg orally.</description>
    <arm_group_label>Thalidomide + Prednisolone [TP Consolidation]</arm_group_label>
    <arm_group_label>Bortezomib + Thalidomide + Prednisolone [VTP Consolidation]</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Previously diagnosed with multiple myeloma based on international myeloma working
             group (IMWG) criteria.and meet all of the following; Serum M-protein greater than or
             equal to (&gt;=) 1 gram per deciliter (g/dL) (&gt;=10 gram per liter); Urine M-protein &gt;=200
             milligram (mg) per 24 hour and Serum Free Light chain (FLC) assay: Involved FLC Level
             &gt;=10 mg/dL (&gt;=100 mg/L) provided serum FLC ratio is normal

          -  Meet the pretreatment laboratory criteria as specified in the study protocol at and
             within 21 days before baseline (Day 1 of Cycle 1, before bortezomib administration for
             induction).

          -  Have ECOG status 0-2.

          -  Men and women must practice an appropriate method of birth control as specified in the
             study protocol from signing of the informed consent form though to the 12-month
             visit/early termination visit.

        Exclusion criteria:

          -  Has previously received treatment for multiple myeloma (including prior therapy with
             radiation or pulsed dexamethasone) as specified in the study protocol.

          -  Has a history of any other malignancy within 5 years before enrolment as specified in
             the study protocol.

          -  Has had major surgery as specified in the study protocol within 30 days before
             enrolment.

          -  Had a myocardial infarction within 6 months of enrolment or has New York Heart
             Association (NYHA) Class III or IV heart failure (or other clinically significant
             cardiac medical history as specified in the study protocol).

          -  Has any condition that, in the opinion of the investigator, would make participation
             not be in the best interest (eg, compromise the well-being) of the patient or that
             could prevent, limit, or confound the protocol-specified assessments.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Asia-Pacific Medical Affairs Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Asia-Pacific Medical Affairs</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Adelaide</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Camperdown</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Geelong</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greenslopes</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heidelberg</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Herston</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Malvern</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nedlands</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newcastle</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Prahran</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sydney</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Westmead</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Woodville South</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Woolloongabba</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hwasun Gun</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ulsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>China</country>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2011</study_first_submitted>
  <study_first_submitted_qc>February 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2012</study_first_posted>
  <results_first_submitted>December 16, 2016</results_first_submitted>
  <results_first_submitted_qc>December 16, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 9, 2017</results_first_posted>
  <last_update_submitted>February 7, 2018</last_update_submitted>
  <last_update_submitted_qc>February 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Bortezomib</keyword>
  <keyword>VELCADE</keyword>
  <keyword>Consolidation therapy</keyword>
  <keyword>Subcutaneous</keyword>
  <keyword>Thalidomide</keyword>
  <keyword>Prednisolone</keyword>
  <keyword>Autologous stem cell transplant (ASCT)</keyword>
  <keyword>VELCADE, cyclophosphamide, dexamethasone (VCD) induction therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The study consisted of 2 treatment phases: induction and consolidation. Participants who completed the induction phase were randomized to enter in the consolidation treatment phase.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Bortezomib + Cyclophosphamide + Dexamethasone [VCD Induction]</title>
          <description>Participants received bortezomib (Velcade) 1.3 milligram per square meter (mg/m^2) subcutaneously (SC) on Days 1, 4, 8, and 11; cyclophosphamide 300 mg/m^2 orally on Days 1, 8, and 15; and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11, and 12 in three 21-day treatment cycles. Participants who completed induction phase entered into the consolidation treatment phase.</description>
        </group>
        <group group_id="P2">
          <title>Thalidomide + Prednisolone [TP Consolidation]</title>
          <description>Participants who completed induction phase entered in the consolidated treatment phase and received thalidomide 100 mg orally, once daily until disease progression (up to maximum of 12 months) and prednisolone 50 mg orally, on every alternate day until disease progression.</description>
        </group>
        <group group_id="P3">
          <title>Bortezomib + Thalidomide + Prednisolone [VTP Consolidation]</title>
          <description>Participants who completed induction phase entered in the consolidated treatment phase and received bortezomib 1.3 mg/m^2 SC every 2 weeks for 32 weeks in addition to thalidomide 100 mg orally, once daily for a maximum of 12 months or until disease progression and prednisolone 50 mg orally, on every alternate day until disease progression.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Before Randomization (VCD Induction)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="256"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="254"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="203"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive Disease</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>After Randomization (TP and VTP)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="100">Participants who completed induction phase were randomized for the consolidated treatment.</participants>
                <participants group_id="P3" count="103">Participants who completed induction phase were randomized for the consolidated treatment.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="99">One participant was randomized but not treated. Hence, was not included in safety population.</participants>
                <participants group_id="P3" count="103"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="87"/>
                <participants group_id="P3" count="92"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive Disease</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline population was defined as all enrolled participants who received at least 1 non-zero dose of any study drug in the induction phase.</population>
      <group_list>
        <group group_id="B1">
          <title>Bortezomib + Cyclophosphamide + Dexamethasone [VCD Induction]</title>
          <description>Participants received bortezomib (Velcade) 1.3 milligram per square meter (mg/m^2) subcutaneously (SC) on Days 1, 4, 8, and 11; cyclophosphamide 300 mg/m^2 orally on Days 1, 8, and 15; and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11, and 12 in three 21-day treatment cycles. Participants who completed induction phase entered into the consolidation treatment phase.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="254"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.8" spread="7.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Republic of Korea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Consolidation Phase: Percentage of Participants With Complete Response (CR) and Very Good Partial Response (VGPR) at Month 12</title>
        <description>CR as per IMWG criteria is defined as negative immunofixation on the serum and urine and disappearance of soft tissue plasmacytomas and less than (&lt;) 5 percent plasma cells in bone marrow. VGPR as per IMWG criteria is defined as serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90 percent or greater reduction in serum M-protein plus urine M-protein level &lt;100 milligram (mg) per 24 hours.</description>
        <time_frame>Month 12</time_frame>
        <population>All response-evaluable-randomized analysis set was defined as all participants in the response-evaluable-induction set (all participants who received at least 1 dose of study medication in the induction phase and had measurable disease at baseline) who were randomized to receive consolidation treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Thalidomide + Prednisolone [TP Consolidation]</title>
            <description>Participants who completed induction phase entered in the consolidated treatment phase and received thalidomide 100 mg orally, once daily until disease progression (up to maximum of 12 months) and prednisolone 50 mg orally, on every alternate day until disease progression.</description>
          </group>
          <group group_id="O2">
            <title>Bortezomib + Thalidomide + Prednisolone [VTP Consolidation]</title>
            <description>Participants who completed induction phase entered in the consolidated treatment phase and received bortezomib 1.3 mg/m^2 SC every 2 weeks for 32 weeks in addition to thalidomide 100 mg orally, once daily for a maximum of 12 months or until disease progression and prednisolone 50 mg orally, on every alternate day until disease progression.</description>
          </group>
        </group_list>
        <measure>
          <title>Consolidation Phase: Percentage of Participants With Complete Response (CR) and Very Good Partial Response (VGPR) at Month 12</title>
          <description>CR as per IMWG criteria is defined as negative immunofixation on the serum and urine and disappearance of soft tissue plasmacytomas and less than (&lt;) 5 percent plasma cells in bone marrow. VGPR as per IMWG criteria is defined as serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90 percent or greater reduction in serum M-protein plus urine M-protein level &lt;100 milligram (mg) per 24 hours.</description>
          <population>All response-evaluable-randomized analysis set was defined as all participants in the response-evaluable-induction set (all participants who received at least 1 dose of study medication in the induction phase and had measurable disease at baseline) who were randomized to receive consolidation treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.3"/>
                    <measurement group_id="O2" value="92.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Consolidation Phase: Percentage of Participants With Complete Response (CR) at Months 3, 6, 9 and 12</title>
        <description>CR as per IMWG criteria is negative immunofixation on serum and urine and disappearance of soft tissue plasmacytomas and &lt;5 percent plasma cells in bone marrow.</description>
        <time_frame>Months 3, 6, 9 and 12</time_frame>
        <population>All response-evaluable-randomized analysis set was defined as all participants in the response-evaluable-induction set (all participants who received at least 1 dose of study medication in the induction phase and had measurable disease at baseline) who were randomized to receive consolidation treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Thalidomide + Prednisolone [TP Consolidation]</title>
            <description>Participants who completed induction phase entered in the consolidated treatment phase and received thalidomide 100 mg orally, once daily until disease progression (up to maximum of 12 months) and prednisolone 50 mg orally, on every alternate day until disease progression.</description>
          </group>
          <group group_id="O2">
            <title>Bortezomib + Thalidomide + Prednisolone [VTP Consolidation]</title>
            <description>Participants who completed induction phase entered in the consolidated treatment phase and received bortezomib 1.3 mg/m^2 SC every 2 weeks for 32 weeks in addition to thalidomide 100 mg orally, once daily for a maximum of 12 months or until disease progression and prednisolone 50 mg orally, on every alternate day until disease progression.</description>
          </group>
        </group_list>
        <measure>
          <title>Consolidation Phase: Percentage of Participants With Complete Response (CR) at Months 3, 6, 9 and 12</title>
          <description>CR as per IMWG criteria is negative immunofixation on serum and urine and disappearance of soft tissue plasmacytomas and &lt;5 percent plasma cells in bone marrow.</description>
          <population>All response-evaluable-randomized analysis set was defined as all participants in the response-evaluable-induction set (all participants who received at least 1 dose of study medication in the induction phase and had measurable disease at baseline) who were randomized to receive consolidation treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.5"/>
                    <measurement group_id="O2" value="36.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.8"/>
                    <measurement group_id="O2" value="44.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.0"/>
                    <measurement group_id="O2" value="52.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.0"/>
                    <measurement group_id="O2" value="53.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Consolidation Phase: Percentage of Participants With Stringent Complete Response (sCR) at Months 3, 6, 9 and 12</title>
        <description>sCR as per IMWG criteria is CR plus normal free light chain (FLC) ratio and absence of clonal cells in bone marrow. CR is negative immunofixation on serum and urine and disappearance of soft tissue plasmacytomas and &lt;5 percent plasma cells in bone marrow.</description>
        <time_frame>Months 3, 6, 9 and 12</time_frame>
        <population>All response-evaluable-randomized analysis set was defined as all participants in the response-evaluable-induction set (all participants who received at least 1 dose of study medication in the induction phase and had measurable disease at baseline) who were randomized to receive consolidation treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Thalidomide + Prednisolone [TP Consolidation]</title>
            <description>Participants who completed induction phase entered in the consolidated treatment phase and received thalidomide 100 mg orally, once daily until disease progression (up to maximum of 12 months) and prednisolone 50 mg orally, on every alternate day until disease progression.</description>
          </group>
          <group group_id="O2">
            <title>Bortezomib + Thalidomide + Prednisolone [VTP Consolidation]</title>
            <description>Participants who completed induction phase entered in the consolidated treatment phase and received bortezomib 1.3 mg/m^2 SC every 2 weeks for 32 weeks in addition to thalidomide 100 mg orally, once daily for a maximum of 12 months or until disease progression and prednisolone 50 mg orally, on every alternate day until disease progression.</description>
          </group>
        </group_list>
        <measure>
          <title>Consolidation Phase: Percentage of Participants With Stringent Complete Response (sCR) at Months 3, 6, 9 and 12</title>
          <description>sCR as per IMWG criteria is CR plus normal free light chain (FLC) ratio and absence of clonal cells in bone marrow. CR is negative immunofixation on serum and urine and disappearance of soft tissue plasmacytomas and &lt;5 percent plasma cells in bone marrow.</description>
          <population>All response-evaluable-randomized analysis set was defined as all participants in the response-evaluable-induction set (all participants who received at least 1 dose of study medication in the induction phase and had measurable disease at baseline) who were randomized to receive consolidation treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.8"/>
                    <measurement group_id="O2" value="23.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.1"/>
                    <measurement group_id="O2" value="28.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.0"/>
                    <measurement group_id="O2" value="30.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.0"/>
                    <measurement group_id="O2" value="28.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Consolidation Phase: Progression Free Survival (PFS)</title>
        <description>PFS, calculated as the time between randomization to disease progression or death (regardless of cause), whichever occurred first. Progressive disease as per IMWG criteria: increase of &gt;= 25 percent from lowest response level in Serum M-component and/or (the absolute increase must be &gt;=0.5 gram per deciliter [g/dL]) Urine M-component and/or (the absolute increase must be &gt;=200 mg/24 hour. Only in participants without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain levels. The absolute increase must be &gt;10 mg/dL. Bone marrow plasma cell percentage: the absolute percent must be &gt;=10 percent. Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas. Development of hypercalcemia (corrected serum calcium &gt;11.5 mg/dL or 2.65 millimole per liter (mmol/L) that can be attributed solely to the plasma cell proliferative disorder.</description>
        <time_frame>Baseline until progressive disease (up to 3 years)</time_frame>
        <population>All response-evaluable-randomized analysis set was defined as all participants in the response-evaluable-induction set (all participants who received at least 1 dose of study medication in the induction phase and had measurable disease at baseline) who were randomized to receive consolidation treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Thalidomide + Prednisolone [TP Consolidation]</title>
            <description>Participants who completed induction phase entered in the consolidated treatment phase and received thalidomide 100 mg orally, once daily until disease progression (up to maximum of 12 months) and prednisolone 50 mg orally, on every alternate day until disease progression.</description>
          </group>
          <group group_id="O2">
            <title>Bortezomib + Thalidomide + Prednisolone [VTP Consolidation]</title>
            <description>Participants who completed induction phase entered in the consolidated treatment phase and received bortezomib 1.3 mg/m^2 SC every 2 weeks for 32 weeks in addition to thalidomide 100 mg orally, once daily for a maximum of 12 months or until disease progression and prednisolone 50 mg orally, on every alternate day until disease progression.</description>
          </group>
        </group_list>
        <measure>
          <title>Consolidation Phase: Progression Free Survival (PFS)</title>
          <description>PFS, calculated as the time between randomization to disease progression or death (regardless of cause), whichever occurred first. Progressive disease as per IMWG criteria: increase of &gt;= 25 percent from lowest response level in Serum M-component and/or (the absolute increase must be &gt;=0.5 gram per deciliter [g/dL]) Urine M-component and/or (the absolute increase must be &gt;=200 mg/24 hour. Only in participants without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain levels. The absolute increase must be &gt;10 mg/dL. Bone marrow plasma cell percentage: the absolute percent must be &gt;=10 percent. Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas. Development of hypercalcemia (corrected serum calcium &gt;11.5 mg/dL or 2.65 millimole per liter (mmol/L) that can be attributed solely to the plasma cell proliferative disorder.</description>
          <population>All response-evaluable-randomized analysis set was defined as all participants in the response-evaluable-induction set (all participants who received at least 1 dose of study medication in the induction phase and had measurable disease at baseline) who were randomized to receive consolidation treatment.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.98" lower_limit="18.46" upper_limit="24.71"/>
                    <measurement group_id="O2" value="19.25" lower_limit="16.66" upper_limit="23.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Consolidation Phase: Disease-free Survival (DFS)</title>
        <description>DFS, defined as the duration from the start of CR to the time of relapse from CR. DFS applied only to participants in CR. CR as per IMWG criteria is negative immunofixation on serum and urine and disappearance of soft tissue plasmacytomas and &lt;5 percent plasma cells in bone marrow. Relapse from CR: reappearance of serum or urine M-protein by immunofixation or electrophoresis; development of &gt;= 5 percent plasma cells in the bone marrow; appearance of any other sign of progression (ie, new plasmacytoma, lytic bone lesion, or hypercalcaemia).</description>
        <time_frame>Up to 3 years</time_frame>
        <population>Response-evaluable-randomized analysis set defined as all participants in the response-evaluable-induction set (who received at least 1 dose of study medication;had measurable disease at baseline) who were randomized to receive consolidation treatment. Here, N (number of participants analyzed) signifies the participants who had complete response.</population>
        <group_list>
          <group group_id="O1">
            <title>Thalidomide + Prednisolone [TP Consolidation]</title>
            <description>Participants who completed induction phase entered in the consolidated treatment phase and received thalidomide 100 mg orally, once daily until disease progression (up to maximum of 12 months) and prednisolone 50 mg orally, on every alternate day until disease progression.</description>
          </group>
          <group group_id="O2">
            <title>Bortezomib + Thalidomide + Prednisolone [VTP Consolidation]</title>
            <description>Participants who completed induction phase entered in the consolidated treatment phase and received bortezomib 1.3 mg/m^2 SC every 2 weeks for 32 weeks in addition to thalidomide 100 mg orally, once daily for a maximum of 12 months or until disease progression and prednisolone 50 mg orally, on every alternate day until disease progression.</description>
          </group>
        </group_list>
        <measure>
          <title>Consolidation Phase: Disease-free Survival (DFS)</title>
          <description>DFS, defined as the duration from the start of CR to the time of relapse from CR. DFS applied only to participants in CR. CR as per IMWG criteria is negative immunofixation on serum and urine and disappearance of soft tissue plasmacytomas and &lt;5 percent plasma cells in bone marrow. Relapse from CR: reappearance of serum or urine M-protein by immunofixation or electrophoresis; development of &gt;= 5 percent plasma cells in the bone marrow; appearance of any other sign of progression (ie, new plasmacytoma, lytic bone lesion, or hypercalcaemia).</description>
          <population>Response-evaluable-randomized analysis set defined as all participants in the response-evaluable-induction set (who received at least 1 dose of study medication;had measurable disease at baseline) who were randomized to receive consolidation treatment. Here, N (number of participants analyzed) signifies the participants who had complete response.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.36" lower_limit="11.24" upper_limit="22.08"/>
                    <measurement group_id="O2" value="16.33" lower_limit="10.61" upper_limit="22.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Consolidation Phase: Overall Survival (OS)</title>
        <description>OS was defined as the time between randomization and death. Death of a participant regardless of the cause was considered as an event.</description>
        <time_frame>Up to 3 years</time_frame>
        <population>All randomized analysis set was defined as participants in the all enrolled set (all participants with a non-missing informed consent date and were not screen failures) who were randomized to receive consolidation treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Thalidomide + Prednisolone [TP Consolidation]</title>
            <description>Participants who completed induction phase entered in the consolidated treatment phase and received thalidomide 100 mg orally, once daily until disease progression (up to maximum of 12 months) and prednisolone 50 mg orally, on every alternate day until disease progression.</description>
          </group>
          <group group_id="O2">
            <title>Bortezomib + Thalidomide + Prednisolone [VTP Consolidation]</title>
            <description>Participants who completed induction phase entered in the consolidated treatment phase and received bortezomib 1.3 mg/m^2 SC every 2 weeks for 32 weeks in addition to thalidomide 100 mg orally, once daily for a maximum of 12 months or until disease progression and prednisolone 50 mg orally, on every alternate day until disease progression.</description>
          </group>
        </group_list>
        <measure>
          <title>Consolidation Phase: Overall Survival (OS)</title>
          <description>OS was defined as the time between randomization and death. Death of a participant regardless of the cause was considered as an event.</description>
          <population>All randomized analysis set was defined as participants in the all enrolled set (all participants with a non-missing informed consent date and were not screen failures) who were randomized to receive consolidation treatment.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Median and 95% CI was not estimable due to insufficient number of events.</measurement>
                    <measurement group_id="O2" value="NA">Median and 95% CI was not estimable due to insufficient number of events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Consolidation Phase: Change From Baseline in AQOL-6D Scores at the End of the Consolidation Phase</title>
        <description>The assessment of quality of life-6D (AQoL-6D) is a multi-attribute health-related quality of life instrument (QoL). It comprises dimension scores for independent living, relationships, mental health, coping, pain, senses, and utility score for AQol-6D. Each scale ranges between 1 (best QoL) and -0.04 (worst possible QoL).</description>
        <time_frame>Baseline, Month 12</time_frame>
        <population>All treated randomized analysis set was defined as participants in the all enrolled set (participants with non-missing informed consent date,not screen failures) received at least 1 dose of any study drug and randomized to receive consolidation treatment. Here, 'N'(number of participants analyzed) participants who were evaluable for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Thalidomide + Prednisolone [TP Consolidation]</title>
            <description>Participants who completed induction phase entered in the consolidated treatment phase and received thalidomide 100 mg orally, once daily until disease progression (up to maximum of 12 months) and prednisolone 50 mg orally, on every alternate day until disease progression.</description>
          </group>
          <group group_id="O2">
            <title>Bortezomib + Thalidomide + Prednisolone [VTP Consolidation]</title>
            <description>Participants who completed induction phase entered in the consolidated treatment phase and received bortezomib 1.3 mg/m^2 SC every 2 weeks for 32 weeks in addition to thalidomide 100 mg orally, once daily for a maximum of 12 months or until disease progression and prednisolone 50 mg orally, on every alternate day until disease progression.</description>
          </group>
        </group_list>
        <measure>
          <title>Consolidation Phase: Change From Baseline in AQOL-6D Scores at the End of the Consolidation Phase</title>
          <description>The assessment of quality of life-6D (AQoL-6D) is a multi-attribute health-related quality of life instrument (QoL). It comprises dimension scores for independent living, relationships, mental health, coping, pain, senses, and utility score for AQol-6D. Each scale ranges between 1 (best QoL) and -0.04 (worst possible QoL).</description>
          <population>All treated randomized analysis set was defined as participants in the all enrolled set (participants with non-missing informed consent date,not screen failures) received at least 1 dose of any study drug and randomized to receive consolidation treatment. Here, 'N'(number of participants analyzed) participants who were evaluable for this endpoint.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Independent Living</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="0.335"/>
                    <measurement group_id="O2" value="0.14" spread="0.397"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relationships</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.300"/>
                    <measurement group_id="O2" value="0.05" spread="0.296"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Health</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.319"/>
                    <measurement group_id="O2" value="0.18" spread="0.270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Coping</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.278"/>
                    <measurement group_id="O2" value="0.05" spread="0.237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="0.373"/>
                    <measurement group_id="O2" value="0.20" spread="0.395"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Senses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.140"/>
                    <measurement group_id="O2" value="0.00" spread="0.137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AQoL-6D Utility score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="0.216"/>
                    <measurement group_id="O2" value="0.11" spread="0.213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Consolidation Phase: Change From Baseline in FACT/GOG-NTX Total Score at the End of the Consolidation Phase</title>
        <description>Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-NTX) consists of 10 items and evaluates symptoms and concerns associated specifically with chemotherapy-induced neuropathy. 1 FACT/GOG-NTX total score has a range of 0 to 108 with a higher score indicating better quality of life.</description>
        <time_frame>Baseline, Month 12</time_frame>
        <population>All treated randomized analysis set was defined as participants in the all enrolled set (participants with non-missing informed consent date,not screen failures) received at least 1 dose of any study drug and randomized to receive consolidation treatment. Here, 'N'(number of participants analyzed) participants who were evaluable for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Thalidomide + Prednisolone [TP Consolidation]</title>
            <description>Participants who completed induction phase entered in the consolidated treatment phase and received thalidomide 100 mg orally, once daily until disease progression (up to maximum of 12 months) and prednisolone 50 mg orally, on every alternate day until disease progression.</description>
          </group>
          <group group_id="O2">
            <title>Bortezomib + Thalidomide + Prednisolone [VTP Consolidation]</title>
            <description>Participants who completed induction phase entered in the consolidated treatment phase and received bortezomib 1.3 mg/m^2 SC every 2 weeks for 32 weeks in addition to thalidomide 100 mg orally, once daily for a maximum of 12 months or until disease progression and prednisolone 50 mg orally, on every alternate day until disease progression.</description>
          </group>
        </group_list>
        <measure>
          <title>Consolidation Phase: Change From Baseline in FACT/GOG-NTX Total Score at the End of the Consolidation Phase</title>
          <description>Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-NTX) consists of 10 items and evaluates symptoms and concerns associated specifically with chemotherapy-induced neuropathy. 1 FACT/GOG-NTX total score has a range of 0 to 108 with a higher score indicating better quality of life.</description>
          <population>All treated randomized analysis set was defined as participants in the all enrolled set (participants with non-missing informed consent date,not screen failures) received at least 1 dose of any study drug and randomized to receive consolidation treatment. Here, 'N'(number of participants analyzed) participants who were evaluable for this endpoint.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="19.68"/>
                    <measurement group_id="O2" value="1.0" spread="19.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Safety population included all participants in the induction and consolidation phase who received at least 1 dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Bortezomib + Cyclophosphamide + Dexamethasone [VCD Induction]</title>
          <description>Participants received bortezomib (Velcade) 1.3 milligram per square meter (mg/m^2) subcutaneously (SC) on Days 1, 4, 8, and 11; cyclophosphamide 300 mg/m^2 orally on Days 1, 8, and 15; and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11, and 12 in three 21-day treatment cycles. Participants who completed induction phase entered into the consolidation treatment phase.</description>
        </group>
        <group group_id="E2">
          <title>Thalidomide + Prednisolone [TP Consolidation]</title>
          <description>Participants who completed induction phase entered in the consolidated treatment phase and received thalidomide 100 mg orally, once daily until disease progression (up to maximum of 12 months) and prednisolone 50 mg orally, on every alternate day until disease progression.</description>
        </group>
        <group group_id="E3">
          <title>Bortezomib + Thalidomide + Prednisolone [VTP Consolidation]</title>
          <description>Participants who completed induction phase entered in the consolidated treatment phase and received bortezomib 1.3 mg/m^2 SC every 2 weeks for 32 weeks in addition to thalidomide 100 mg orally, once daily for a maximum of 12 months or until disease progression and prednisolone 50 mg orally, on every alternate day until disease progression.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 14.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="88" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Atrial Flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Left Ventricular Dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Sinus Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Supraventricular Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blepharitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain Lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Oesophageal Spasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Rectal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse Drug Reaction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Non-Cardiac Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Anal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Bacillus Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Device Related Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Hepatitis B</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Herpes Zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Herpes Zoster Disseminated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Lobar Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Localised Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Lower Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Lung Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Nocardiosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Pneumonia Influenzal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Pneumonia Primary Atypical</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Rhinovirus Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Staphylococcal Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Subcutaneous Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Viral Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Lumbar Vertebral Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Rib Fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Road Traffic Accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Spinal Compression Fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Spinal Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Subdural Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Thoracic Vertebral Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Cytomegalovirus Test Positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Bone Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Muscular Weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Osteolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Pathological Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Squamous Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Thyroid Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Transitional Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Embolic Stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Spinal Cord Compression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Renal Impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Diaphragmatic Paralysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Organising Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Pulmonary Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Respiratory Distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Decubitus Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Drug Eruption</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Circulatory Collapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Embolism Venous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Orthostatic Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Peripheral Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA Version 14.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="233" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="95" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="96" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Cushingoid</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision Blurred</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Visual Impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="91" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Injection Site Rash</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Injection Site Reaction</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Herpes Zoster</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Lower Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight Increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Muscular Weakness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Neuropathy Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Peripheral Sensory Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Mood Altered</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Dyspnoea Exertional</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Leader</name_or_title>
      <organization>Janssen R&amp;D</organization>
      <email>ClinicalTrialDisclosure@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

